How DaVita makes money
Fiscal 2025, year ended Dec 31, 2025 · 10-K filed with the SEC
DaVita brought in $13.6B of revenue in fiscal 2025 (+6.5% on the year before). 15.0% of revenue was left as operating profit and 5.5% as net income.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Fiscal 2025, year ended Dec 31, 2025 · 10-K filed with the SEC
DaVita brought in $13.6B of revenue in fiscal 2025 (+6.5% on the year before). 15.0% of revenue was left as operating profit and 5.5% as net income.
DaVita reports 2 business segments: U S Dialysis and Other - Ancillary services. U S Dialysis is the largest, with $11.7B in fiscal 2025, 86% of revenue. Other - Ancillary services grew fastest, +28% on the year before.
Fiscal 2025, year ended Dec 31, 2025, from the revenue DaVita broke down in its 10-K filed Feb 11, 2026. The split is the company’s own; regions are usually where customers are billed, not where products end up.
| Line | Fiscal 2024 | Fiscal 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.8B | $13.6B | $828M | +6.5% |
| Operating profit | $2.09B | $2.04B | −$46.9M | −2.2% |
| General and administrative | $1.54B | $1.67B | +$135M | +8.8% |
| Other operating costs | $9.19B | $9.93B | +$739M | +8.0% |
| Net income | $936M | $747M | −$190M | −20.2% |
| Income tax | $280M | $293M | +$13.5M | +4.8% |
| Interest and other | $874M | $1B | +$129M | +14.8% |
| In US dollars | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7B | $10.9B | $11.4B | $11.4B | $11.6B | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Growth | — | +1.6% | +4.9% | −0.1% | +1.4% | +0.6% | −0.1% | +4.6% | +5.6% | +6.5% |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Sales, general and admin | $1.07B | $1.06B | $1.14B | $1.1B | $1.25B | $1.2B | $1.36B | $1.47B | $1.54B | $1.67B |
| Other operating costs | $7.6B | $8B | $8.74B | $8.64B | $8.61B | $8.63B | $8.92B | $9.06B | $9.19B | $9.93B |
| Operating income | $2.03B | $1.81B | $1.53B | $1.64B | $1.69B | $1.8B | $1.34B | $1.6B | $2.09B | $2.04B |
| Operating margin | 19.0% | 16.7% | 13.4% | 14.4% | 14.7% | 15.5% | 11.5% | 13.2% | 16.3% | 15.0% |
| Interest expense | $414M | $431M | $487M | $444M | $304M | $285M | $357M | $399M | $470M | $580M |
| Pre-tax income | $1.62B | $1.4B | $1.05B | $1.2B | $1.32B | $1.52B | $966M | $1.18B | $1.53B | $1.35B |
| Income tax | $432M | $324M | $258M | $280M | $314M | $307M | $198M | $220M | $280M | $293M |
| Effective tax rate | 26.6% | 23.1% | 24.6% | 23.4% | 23.8% | 20.2% | 20.5% | 18.7% | 18.3% | 21.8% |
| Net income | $880M | $664M | $159M | $811M | $774M | $978M | $560M | $692M | $936M | $747M |
| Net margin | 8.2% | 6.1% | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
“—” means the company did not tag that line that year in the standard US taxonomy, not zero. Banks and insurers report no gross or operating profit. “Sales, general and admin” adds sales and marketing to general and administrative when the company reports them apart. Other operating costs are what is left between gross and operating profit after the lines the company tagged.
Twenty years of cash flow, buybacks and debt: DaVita financial history. Margins and valuation next to its industry: DaVita vs its peers. The latest quarter, insider trades and fund moves: DaVita (DVA) on OQRO.
DaVita reports 2 business segments: U S Dialysis and Other - Ancillary services. U S Dialysis is the largest, with $11.7B in fiscal 2025, 86% of revenue. Other - Ancillary services grew fastest, +28% on the year before.
DaVita: Health Care Services company based in Denver, Colorado. It is listed in the Health Care Services industry, Health Care sector. It reports its business as 2 segments: U S Dialysis, Other - Ancillary services.
$13.6B, in the fiscal year that ended Dec 31, 2025, as reported in its 10-K. That is +6.5% on fiscal 2024 ($12.8B).
Net income of $747M, after an operating profit of $2.04B and income tax of $293M.
The SEC’s companyfacts data: the full-year figures DaVita tagged in XBRL in its annual reports (10-K, 20-F or 40-F). When a later report restates a year, the later figure is used. Revenue, cost of revenue, gross profit, research and development, selling, general and administrative costs, operating income, pre-tax income, income tax and net income are the company’s own lines.
Lines marked * are differences: other operating costs are gross profit minus operating profit minus the cost lines the company tagged; “interest and other” is operating profit minus tax minus net income, so it holds interest, investment gains and losses, minority stakes and discontinued operations together. When the tagged cost of revenue and gross profit disagree, the company’s gross profit is kept. The segment, product and region splits come from the dimensioned revenue facts of the latest annual report’s XBRL instance: a split is shown only when its parts add up to the company’s total revenue within 1%, and labels are the company’s own. This page describes the past and is not investment advice. No language model wrote it.